Literature DB >> 16905423

New therapies for the treatment of inflammatory bowel disease.

Bruce E Sands1.   

Abstract

Medical therapy of IBD has made remarkable progress in recent years, driven forward by new knowledge about mechanisms of disease and advances in biotechnology. As we continue to learn about how best to use the agents currently in our hands, the addition of new drugs will further improve outcomes, and will bring new insights into the fundamental causes of these diseases.

Entities:  

Mesh:

Year:  2006        PMID: 16905423     DOI: 10.1016/j.suc.2006.05.009

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  6 in total

1.  An old herbal medicine with a potentially new therapeutic application in inflammatory bowel disease.

Authors:  Richard Li; Philip Alex; Mei Ye; Ting Zhang; Ling Liu; Xuhang Li
Journal:  Int J Clin Exp Med       Date:  2011-10-29

2.  Amelioration of severe TNBS induced colitis by novel AP-1 and NF- κ B inhibitors in rats.

Authors:  Magdy El-Salhy; Kazuo Umezawa; Odd Helge Gilja; Jan G Hatlebakk; Doris Gundersen; Trygve Hausken
Journal:  ScientificWorldJournal       Date:  2014-01-30

3.  Anti-inflammatory effects of novel AP-1 and NF-κB inhibitors in dextran-sulfate-sodium-induced colitis in rats.

Authors:  Magdy El-Salhy; Kazuo Umezawa
Journal:  Int J Mol Med       Date:  2016-04-12       Impact factor: 4.101

Review 4.  Gastrointestinal neuroendocrine peptides/amines in inflammatory bowel disease.

Authors:  Magdy El-Salhy; Tefera Solomon; Trygve Hausken; Odd Helge Gilja; Jan Gunnar Hatlebakk
Journal:  World J Gastroenterol       Date:  2017-07-28       Impact factor: 5.742

5.  Changes in enteroendocrine and immune cells following colitis induction by TNBS in rats.

Authors:  Magdy El-Salhy; Jan Gunnar Hatlebakk
Journal:  Mol Med Rep       Date:  2016-10-31       Impact factor: 2.952

6.  Abnormalities in endocrine and immune cells are correlated in dextran‑sulfate‑sodium‑induced colitis in rats.

Authors:  Magdy El-Salhy; Jan Gunnar Hatlebakk; Odd Helge Gilja
Journal:  Mol Med Rep       Date:  2016-12-12       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.